Analyzing Invivo Therapeutics (NASDAQ:NVIV) and Vapotherm (NASDAQ:VAPO)

Vapotherm (NYSE:VAPO) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares Vapotherm and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vapotherm -110.06% -107.95% -50.80%
Invivo Therapeutics N/A -91.56% -73.10%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vapotherm and Invivo Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm 0 0 4 0 3.00
Invivo Therapeutics 0 0 0 0 N/A

Vapotherm presently has a consensus price target of $19.50, suggesting a potential upside of 85.54%. Given Vapotherm’s higher possible upside, equities research analysts plainly believe Vapotherm is more favorable than Invivo Therapeutics.

Institutional & Insider Ownership

47.7% of Vapotherm shares are held by institutional investors. Comparatively, 6.8% of Invivo Therapeutics shares are held by institutional investors. 34.4% of Vapotherm shares are held by insiders. Comparatively, 0.3% of Invivo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vapotherm and Invivo Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vapotherm $42.38 million 5.23 -$42.47 million ($13.83) -0.76
Invivo Therapeutics N/A N/A -$23.42 million ($2.25) -0.10

Invivo Therapeutics has lower revenue, but higher earnings than Vapotherm. Vapotherm is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vapotherm beats Invivo Therapeutics on 6 of the 11 factors compared between the two stocks.

Vapotherm Company Profile

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Invivo Therapeutics Company Profile

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.